Menogaril in the treatment of malignant mesothelioma: A phase II study Journal Article
| Authors: | Hudis, C. A.; Kelsen, D. P. |
| Article Title: | Menogaril in the treatment of malignant mesothelioma: A phase II study |
| Abstract: | Menogaril is a new semisynthetic anthracycline agent derived from the antitumor antibiotic Nogalomycin. Compared to doxorubicin it has similar or improved activity in anti-tumor cell line screening; human tumor cloning assays suggest modest anti-tumor activity as well. Menogaril is much less cardiotoxic than doxorubicin. We performed a phase II trial of this agent in 22 patients with advanced malignant mesothelioma. At a dose of 200 mg/m2 iv every 4 weeks (160 mg/m2 in previously radiated patients) only 1 of 22 (5%) evaluable patients had a partial remission lasting 4 months. (95% confidence limits 0.1-23%). The major toxic effects included pain at the site of infusion and granulocytopenia. While well tolerated, Menogaril has minimal activity in malignant mesothelioma. We do not plan further studies with Menogaril in this disease. © 1992 Kluwer Academic Publishers. |
| Keywords: | adult; clinical article; treatment outcome; aged; aged, 80 and over; clinical feature; doxorubicin; advanced cancer; dose response; drug efficacy; antineoplastic agents; cancer radiotherapy; phase 2 clinical trial; bone marrow suppression; gastrointestinal symptom; mucosa inflammation; antineoplastic activity; drug fever; cancer regression; malignant mesothelioma; mesothelioma; blood cell count; phase ii; dose calculation; intravenous drug administration; middle age; drug evaluation; menogaril; injection pain; human; male; female; priority journal; article; nogalamycin; support, u.s. gov't, p.h.s. |
| Journal Title: | Investigational New Drugs |
| Volume: | 10 |
| Issue: | 2 |
| ISSN: | 0167-6997 |
| Publisher: | Springer |
| Date Published: | 1992-06-01 |
| Start Page: | 103 |
| End Page: | 106 |
| Language: | English |
| DOI: | 10.1007/bf00873126 |
| PUBMED: | 1386842 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work